Search by property

This page provides a simple browsing interface for finding entities described by a property and a named value. Other available search interfaces include the page property search, and the ask query builder.

List of results

• Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial  + (NI)
• Martin et al. (2002): Does prophylactic treatment with proteolytic enzymes reduce acute toxicity of adjuvant pelvic irradiation? Results of a double-blind randomized trial  + (NI)
• Okabayashi et al. (2020): L-Carnitine Improves Postoperative Liver Function in Hepatectomized Patients  + (NI)
• Hoopfer et al. (2015): Three-arm randomized phase III trial: Quality aloe and placebo cream versus powder as skin treatment during breast cancer radiation therapy  + (NI)
• Hoopfer et al. (2015): Three-arm randomized phase III trial: Quality aloe and placebo cream versus powder as skin treatment during breast cancer radiation therapy  + (NI)
• Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer  + (NI)
• Marucci et al. (2017): Double-blind randomized phase III study comparing a mixture of natural agents versus placebo in the prevention of acute mucositis during chemoradiotherapy for head and neck cancer  + (NI)
• Raei et al. (2013): Effect of herbal therapy to intensity chemotherapy-induced nausea and vomiting in cancer patients  + (NI)
• Li et al. (2018): Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial  + (NI)
• Li et al. (2018): Efficacy of Ginger in Ameliorating Acute and Delayed Chemotherapy-Induced Nausea and Vomiting Among Patients With Lung Cancer Receiving Cisplatin-Based Regimens: A Randomized Controlled Trial  + (NI)
• Bairati et al. (2005): Randomized Trial of Antioxidant Vitamins to Prevent Acute Adverse Effects of Radiation Therapy in Head and Neck Cancer Patients  + (NI)
• Sanaati et al. (2016): Effect of Ginger and Chamomile on Nausea and Vomiting Caused by Chemotherapy in Iranian Women with Breast Cancer  + (NI: data collected but not reported)
• Ansari et al. (2016): Efficacy of Ginger in Control of Chemotherapy Induced Nausea and Vomiting in Breast Cancer Patients Receiving Doxorubicin- Based Chemotherapy  + (Nausea (all three cycles): no significant difference for mean nausea in ginger vs. placebo arm Subgroup analysis for different chemotherapies: no significant arm differences)
• Thamlikitkul et al. (2017): Efficacy of ginger for prophylaxis of chemotherapy-induced nausea and vomiting in breast cancer patients receiving adriamycin–cyclophosphamide regimen: a randomized, double-blind, placebo-controlled, crossover study  + (Nausea score max: T0 (during first chemoth … Nausea score max: T0 (during first chemotherapy) (Mean (range)): 58 (40-90), T1 (0-24h) intervention vs. placebo Mean(SD): p=0.64, T2 (>24h) intervention vs. placebo Mean(SD: p=0.21, total intervention vs. placebo Mean(SD): p=0.30</br>No significant differencebo Mean(SD): p=0.30 No significant difference)
• Rostock et al. (2013): Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients: A Four-Arm Randomized Trial on the Effectiveness of Electroacupuncture  + (Neuropathy score decreased in all arms during treatment (from day 0 until day 21); no significant differences between any two arms (no p-values reported))
• Khodabakhshi et al. (2019): Feasibility, Safety, and Beneficial Effects of MCT-Based Ketogenic Diet for Breast Cancer Treatment: A Randomized Controlled Trial Study  + (No arm difference in survival rate after 9 weeks)
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No arm differences after 5 weeks (no p-value).)
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No arm differences after 5 weeks (no p-value).)
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No arm differences after 5 weeks (no p-value).)
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No arm differences after 5 weeks (no p-value).)
• Fallon et al. (2017) II: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No arm differences after 5 weeks (no p-value).)
• Sangthawan et al. (2013): A randomized double-blind, placebo-controlled trial of zinc sulfate supplementation for alleviation of radiation-induced oral mucositis and pharyngitis in head and neck cancer patients  + (No baseline differences concerning oral pa … No baseline differences concerning oral pain, but significant differences in the mean scores of throat pain (placebo: 0.17 (SD 0.75) vs. intervention: 0.36 (SD 1.21), p<0.05),</br>there were no statistically significant differences between the two arms during radiation time;</br></br>The frequency of using analgesic medication were not significantly different between armswere not significantly different between arms)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (No comparison between arms conducted.)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (No comparison between arms conducted.)
• Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer  + (No complete responses were observed, partial objective response rate was not significantly different, neither was stable disease rate)
• Liu et al. (2010): Influence of vitamin C on salivary absorbed dose of 131I in thyroid cancer patients: a prospective, randomized, single-blind, controlled trial  + (No data available)

• Hershman et al. (2013): Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy  + (No difference between arms)
• Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology  + (No difference between arms)
• Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology  + (No difference between arms)

• Hershman et al. (2013): Randomized Double-Blind Placebo-Controlled Trial of Acetyl-L-Carnitine for the Prevention of Taxane-Induced Neuropathy in Women Undergoing Adjuvant Breast Cancer Therapy  + (No difference between arms (12 weeks: p=0.20; 24 weeks: p=0.51), higher values in both arms over time)
• Jahangard-Rafsanjani et al. (2013): The efficacy of selenium in prevention of oral mucositis in patients undergoing hematopoietic SCT: a randomized clinical trial  + (No difference between arms (p=0.32, p=0.87))
• Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial  + (No difference between arms (p=0.4270), even after controlling for tumor site, treatment method and cancer stage at week 7 or the entire study period)
• Kraft et al. (2012): L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial  + (No difference between arms and/or points in time)
• Kraft et al. (2012): L-Carnitine-supplementation in advanced pancreatic cancer (CARPAN) - a randomized multicentre trial  + (No difference between arms and/or points in time)
• Muecke et al. (2010): Multicenter, phase 3 trial comparing selenium supplementation with observation in gynecologic radiation oncology  + (No difference between arms at baseline, bu … No difference between arms at baseline, but significantly higher in the intervention arm than the control arm at mid-study (intervention arm: 93.2 µg/L vs. control arm: 67.3 µg/L) and end of study (intervention arm: 90.9±19.9 µg/L vs. control arm: 61.4±15.5 µg/L; p < 0.001)s. control arm: 61.4±15.5 µg/L; p < 0.001))
• Cruciani et al. (2012): L-Carnitine Supplementation for the Management of Fatigue in Patients With Cancer: An Eastern Cooperative Oncology Group Phase III, Randomized, Double-Blind, Placebo-Controlled Trial  + (No difference between arms for grade 5 side effect (Fisher's exact p=0.64))
• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (No difference between arms.)
• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (No difference between arms.)
• Barton et al. (2013): The use of Ginkgo biloba for the prevention of chemotherapy-related cognitive dysfunction in women receiving adjuvant treatment for breast cancer, N00C9  + (No difference between arms.)
• Sahebnasagh et al. (2017): Successful Treatment of Acute Radiation Proctitis with Aloe Vera: A Preliminary Randomized Controlled Clinical Trial  + (No difference between the arms.)
• Attia et al. (2008): Randomized, Double-Blinded Phase II Evaluation of Docetaxel with or without Doxercalciferol in Patients with Metastatic, Androgen-Independent Prostate Cancer  + (No difference between treatment arms in the rate of PSA response, no difference in the median time to PSA response)
• Frankling et al. (2021): ‘Palliative-D’ - Vitamin D Supplementation to Palliative Cancer Patients: A Double Blind, Randomized Placebo-Controlled Multicenter Trial  + (No difference in survival time between the two treatment arms at any timepoint, after 4 weeks (p=0.36), 8 weeks (p=0.09) or 12 weeks (p=0.08))
• Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No differences between arms after 5 weeks (no p-value))
• Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No differences between arms after 5 weeks (no p-value).)
• Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No differences between arms after 5 weeks (no p-value).)
• Fallon et al. (2017) I: Sativex oromucosal spray as adjunctive therapy in advanced cancer patients with chronic pain unalleviated by optimized opioid therapy: two double-blind, randomized, placebo-controlled phase 3 studies  + (No differences between arms after 5 weeks (no p-value).)
• Koyama et al. (2017): Intravenous Carnitine Administration in Addition to Parenteral Nutrition With Lipid Emulsion May Decrease the Inflammatory Reaction in Postoperative Surgical Patients  + (No differences between the arms for complications (in both arms n=2 each; p=0.715) or type of complication (p>0.05))
• Côté et al. (2016): Improving Quality of Life With Nabilone During Radiotherapy Treatments for Head and Neck Cancers: A Randomized Double-Blind Placebo-Controlled Trial  + (No differences for sleepiness (p=0.3166), anxiety (p=0.9163) and xerostomia (p=0.8341))
• Strasser et al. (2006): Comparison of orally administered cannabis extract and delta-9-tetrahydrocannabinol in treating patients with cancer-related anorexia-cachexia syndrome: a multicenter, phase III, randomized, double-blind, placebo-controlled (…)  + (No differences for weight or weight loss after 6 weeks (no statistical values))
• Sahebjamee et al. (2015): Comparative Efficacy of Aloe vera and Benzydamine Mouthwashes on Radiation-induced Oral Mucositis: A Triple-blind, Randomised, Controlled Clinical Trial  + (No grade 4 was identified in both arms. … No grade 4 was identified in both arms. </br></br>The mean time between the start of radiation and onset of early signs of mucositis was 15.6 days in the</br>Aloe arm and 15.8 days in the placebo arm, but the difference was not statistically significant (p = 0.97).</br>The mean duration between beginning of radiation and maximum mucositis grade occurrence was 23.3 days in the Aloe arm and 23.5 days in the placebo arm, but the difference was not statistically significant (p = 0.98).</br></br>There was no significant difference between the arms in terms of mucositis grade changes over time (p = 0.09).ositis grade changes over time (p = 0.09).)
• Uysal et al. (2016): Effects of foot massage applied in two different methods on symptom control in colorectal cancer patients: Randomised control trial  + (No information)
• Lissoni et al. (1998): Biotherapy with the Pineal Immunomodulating Hormone Melatonin versus Melatonin plus Aloe vera in Untreatable Advanced Solid Neoplasms  + (No objective tumor regression was achieved … No objective tumor regression was achieved in the control arm. In contrast, 2/24 (8%) patients of the aloe arm had partial response. Stable disease was obtained in 12/24 (50%) patients of the aloe arm and in only 7/26 (27%) patients of the control arm. </br>There were significantly fewer patients with non-progressive disease in the aloe arm (14/24) compared to control arm (7/26), p<0.05. </br>7/24 (42%) patients of the aloe arm and 19/26 (73%) patients of the control arm had progressive disease.s of the control arm had progressive disease.)
• Mantovani et al. (2010): Randomized Phase III Clinical Trial of Five Different Arms of Treatment in 332 Patients with Cancer Cachexia  + (No sign. difference between arms (p=NI))